To explore the potential of RBM38 to function as a tumor suppressor by repressing c-Myc expression in breast cancer, we used two specific c-Myc inhibitors, 10058-F4 and 10074-G5, which target c-Myc/Max dimerization and inhibit the c-Myc-Max interaction to prevent transactivation of c-Myc target genes [29, 30]. This evidence concerns the gene MYC and breast cancer.